Shots:
- In the P-I study, the companies will evaluate the OBDS with Ionis’ drug for in vitro compatibility and performance as well as in vivo safety, tolerability, and performance in a preclinical canine model
- Progenity expects that the alliance could demonstrate the versatility of OBDS in delivering a range of different molecules
- Ionis’ novel antisense therapies are designed to target mRNA, either decrease disease-causing proteins or increase the production of a needed protein while Progenity’s OBDS is an ingestible capsule based on a needle-free technology to enable the delivery of a drug formulated in a solution directly into the tissues of the small intestine
Click here to read full press release/ article | Ref: GlobeNewswire | Image: BusinessWire
The post Progenity Signs an Agreement with Ionis Pharmaceuticals to Evaluate Oral Biotherapeutics Delivery System with Antisense Oligonucleotides first appeared on PharmaShots.
